tetano
Editor, Senior Moderator
Nat Commun
. 2022 Mar 10;13(1):1251.
doi: 10.1038/s41467-022-28898-1.
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Adriana Tomic[SUP] #[/SUP][SUP] 1 [/SUP], Donal T Skelly[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Ane Ogbe[SUP] #[/SUP][SUP] 2 [/SUP], Daniel O'Connor[SUP] #[/SUP][SUP] 5 6 [/SUP], Matthew Pace[SUP] 2 [/SUP], Emily Adland[SUP] 2 [/SUP], Frances Alexander[SUP] 7 [/SUP], Mohammad Ali[SUP] 2 [/SUP], Kirk Allott[SUP] 8 [/SUP], M Azim Ansari[SUP] 2 [/SUP], Sandra Belij-Rammerstorfer[SUP] 9 [/SUP], Sagida Bibi[SUP] 5 [/SUP], Luke Blackwell[SUP] 5 [/SUP], Anthony Brown[SUP] 2 [/SUP], Helen Brown[SUP] 2 [/SUP], Breeze Cavell[SUP] 7 [/SUP], Elizabeth A Clutterbuck[SUP] 5 [/SUP], Thushan de Silva[SUP] 10 [/SUP], David Eyre[SUP] 3 11 [/SUP], Sheila Lumley[SUP] 2 3 [/SUP], Amy Flaxman[SUP] 9 [/SUP], James Grist[SUP] 12 [/SUP], Carl-Philipp Hackstein[SUP] 2 [/SUP], Rachel Halkerston[SUP] 7 [/SUP], Adam C Harding[SUP] 13 [/SUP], Jennifer Hill[SUP] 5 6 [/SUP], Tim James[SUP] 8 [/SUP], Cecilia Jay[SUP] 2 [/SUP], Síle A Johnson[SUP] 2 3 14 [/SUP], Barbara Kronsteiner[SUP] 2 15 [/SUP], Yolanda Lie[SUP] 16 [/SUP], Aline Linder[SUP] 5 6 [/SUP], Stephanie Longet[SUP] 7 17 [/SUP], Spyridoula Marinou[SUP] 5 6 [/SUP], Philippa C Matthews[SUP] 2 3 6 [/SUP], Jack Mellors[SUP] 7 [/SUP], Christos Petropoulos[SUP] 16 [/SUP], Patpong Rongkard[SUP] 2 18 [/SUP], Cynthia Sedik[SUP] 16 [/SUP], Laura Silva-Reyes[SUP] 5 6 [/SUP], Holly Smith[SUP] 9 [/SUP], Lisa Stockdale[SUP] 5 6 [/SUP], Stephen Taylor[SUP] 7 [/SUP], Stephen Thomas[SUP] 7 [/SUP], Timothy Tipoe[SUP] 2 [/SUP], Lance Turtle[SUP] 19 20 [/SUP], Vinicius Adriano Vieira[SUP] 21 [/SUP], Terri Wrin[SUP] 16 [/SUP], OPTIC Clinical Group; PITCH Study Group; C-MORE Group; Andrew J Pollard[SUP] 5 6 [/SUP], Teresa Lambe[SUP] 9 [/SUP], Chris P Conlon[SUP] 22 [/SUP], Katie Jeffery[SUP] 3 23 [/SUP], Simon Travis[SUP] 3 24 [/SUP], Philip Goulder[SUP] 21 [/SUP], John Frater[SUP] 2 3 [/SUP], Alex J Mentzer[SUP] 3 17 [/SUP], Lizzie Stafford[SUP] 22 [/SUP], Miles W Carroll[SUP] 7 17 [/SUP], William S James[SUP] 13 [/SUP], Paul Klenerman[SUP] #[/SUP][SUP] 2 3 6 24 [/SUP], Eleanor Barnes[SUP] #[/SUP][SUP] 25 26 27 28 [/SUP], Christina Dold[SUP] #[/SUP][SUP] 5 6 [/SUP], Susanna J Dunachie[SUP] #[/SUP][SUP] 2 3 15 18 [/SUP]
Collaborators, Affiliations
Abstract
The trajectories of acquired immunity to severe acute respiratory syndrome coronavirus 2 infection are not fully understood. We present a detailed longitudinal cohort study of UK healthcare workers prior to vaccination, presenting April-June 2020 with asymptomatic or symptomatic infection. Here we show a highly variable range of responses, some of which (T cell interferon-gamma ELISpot, N-specific antibody) wane over time, while others (spike-specific antibody, B cell memory ELISpot) are stable. We use integrative analysis and a machine-learning approach (SIMON - Sequential Iterative Modeling OverNight) to explore this heterogeneity. We identify a subgroup of participants with higher antibody responses and interferon-gamma ELISpot T cell responses, and a robust trajectory for longer term immunity associates with higher levels of neutralising antibodies against the infecting (Victoria) strain and also against variants B.1.1.7 (alpha) and B.1.351 (beta). These variable trajectories following early priming may define subsequent protection from severe disease from novel variants.
. 2022 Mar 10;13(1):1251.
doi: 10.1038/s41467-022-28898-1.
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Adriana Tomic[SUP] #[/SUP][SUP] 1 [/SUP], Donal T Skelly[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Ane Ogbe[SUP] #[/SUP][SUP] 2 [/SUP], Daniel O'Connor[SUP] #[/SUP][SUP] 5 6 [/SUP], Matthew Pace[SUP] 2 [/SUP], Emily Adland[SUP] 2 [/SUP], Frances Alexander[SUP] 7 [/SUP], Mohammad Ali[SUP] 2 [/SUP], Kirk Allott[SUP] 8 [/SUP], M Azim Ansari[SUP] 2 [/SUP], Sandra Belij-Rammerstorfer[SUP] 9 [/SUP], Sagida Bibi[SUP] 5 [/SUP], Luke Blackwell[SUP] 5 [/SUP], Anthony Brown[SUP] 2 [/SUP], Helen Brown[SUP] 2 [/SUP], Breeze Cavell[SUP] 7 [/SUP], Elizabeth A Clutterbuck[SUP] 5 [/SUP], Thushan de Silva[SUP] 10 [/SUP], David Eyre[SUP] 3 11 [/SUP], Sheila Lumley[SUP] 2 3 [/SUP], Amy Flaxman[SUP] 9 [/SUP], James Grist[SUP] 12 [/SUP], Carl-Philipp Hackstein[SUP] 2 [/SUP], Rachel Halkerston[SUP] 7 [/SUP], Adam C Harding[SUP] 13 [/SUP], Jennifer Hill[SUP] 5 6 [/SUP], Tim James[SUP] 8 [/SUP], Cecilia Jay[SUP] 2 [/SUP], Síle A Johnson[SUP] 2 3 14 [/SUP], Barbara Kronsteiner[SUP] 2 15 [/SUP], Yolanda Lie[SUP] 16 [/SUP], Aline Linder[SUP] 5 6 [/SUP], Stephanie Longet[SUP] 7 17 [/SUP], Spyridoula Marinou[SUP] 5 6 [/SUP], Philippa C Matthews[SUP] 2 3 6 [/SUP], Jack Mellors[SUP] 7 [/SUP], Christos Petropoulos[SUP] 16 [/SUP], Patpong Rongkard[SUP] 2 18 [/SUP], Cynthia Sedik[SUP] 16 [/SUP], Laura Silva-Reyes[SUP] 5 6 [/SUP], Holly Smith[SUP] 9 [/SUP], Lisa Stockdale[SUP] 5 6 [/SUP], Stephen Taylor[SUP] 7 [/SUP], Stephen Thomas[SUP] 7 [/SUP], Timothy Tipoe[SUP] 2 [/SUP], Lance Turtle[SUP] 19 20 [/SUP], Vinicius Adriano Vieira[SUP] 21 [/SUP], Terri Wrin[SUP] 16 [/SUP], OPTIC Clinical Group; PITCH Study Group; C-MORE Group; Andrew J Pollard[SUP] 5 6 [/SUP], Teresa Lambe[SUP] 9 [/SUP], Chris P Conlon[SUP] 22 [/SUP], Katie Jeffery[SUP] 3 23 [/SUP], Simon Travis[SUP] 3 24 [/SUP], Philip Goulder[SUP] 21 [/SUP], John Frater[SUP] 2 3 [/SUP], Alex J Mentzer[SUP] 3 17 [/SUP], Lizzie Stafford[SUP] 22 [/SUP], Miles W Carroll[SUP] 7 17 [/SUP], William S James[SUP] 13 [/SUP], Paul Klenerman[SUP] #[/SUP][SUP] 2 3 6 24 [/SUP], Eleanor Barnes[SUP] #[/SUP][SUP] 25 26 27 28 [/SUP], Christina Dold[SUP] #[/SUP][SUP] 5 6 [/SUP], Susanna J Dunachie[SUP] #[/SUP][SUP] 2 3 15 18 [/SUP]
Collaborators, Affiliations
- PMID: 35273178
- DOI: 10.1038/s41467-022-28898-1
Abstract
The trajectories of acquired immunity to severe acute respiratory syndrome coronavirus 2 infection are not fully understood. We present a detailed longitudinal cohort study of UK healthcare workers prior to vaccination, presenting April-June 2020 with asymptomatic or symptomatic infection. Here we show a highly variable range of responses, some of which (T cell interferon-gamma ELISpot, N-specific antibody) wane over time, while others (spike-specific antibody, B cell memory ELISpot) are stable. We use integrative analysis and a machine-learning approach (SIMON - Sequential Iterative Modeling OverNight) to explore this heterogeneity. We identify a subgroup of participants with higher antibody responses and interferon-gamma ELISpot T cell responses, and a robust trajectory for longer term immunity associates with higher levels of neutralising antibodies against the infecting (Victoria) strain and also against variants B.1.1.7 (alpha) and B.1.351 (beta). These variable trajectories following early priming may define subsequent protection from severe disease from novel variants.